申请人:Sucholeiki Irving
公开号:US20110230452A1
公开(公告)日:2011-09-22
The present invention relates generally to pharmaceutical agents, and in particular, to metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of dual acting MMP-2 and MMP-9 inhibiting compounds that exhibit increased potency, metabolic stability and/or reduced toxicity in relation to currently known MMP-2 and MMP-9 inhibitors for the treatment of pain and other diseases. Additionally, the present invention relates to methods for treating pain, addiction and/or withdrawal symptoms in a patient comprising administering to the patient a pain-reducing effective amount of a present compound.
本发明通常涉及制药剂,特别是金属蛋白酶抑制剂化合物。更具体地,本发明提供了一类新的双重作用MMP-2和MMP-9抑制化合物,这些化合物在与目前已知的MMP-2和MMP-9抑制剂相比具有增强的效力、代谢稳定性和/或降低的毒性,用于治疗疼痛和其他疾病。此外,本发明涉及一种治疗疼痛、成瘾和/或戒断症状的方法,包括向患者施用一定量的具有减轻疼痛作用的本发明化合物。